Mechanistic Evidence: Why This Might Work A 2025 narrative review explored whether tirzepatide could act as a disease-modifying therapy for lipedema (Viana et al., 2025)
Mounjaro (tirzepatide) Disease area(s): Metabolic diseases Manufacturer(s): Eli Lilly and Company 2024 Sales (USD): $11.54 billion Why it sold so well: Eli Lillys dual GIP and GLP-1 receptor agonist for type 2 diabetes, Mounjaro, experienced exceptional growth in 2024, with global sales more than doubling to $11.54 billion
Still, many people are now wondering if Vitamin B12 shots and other supplements can help them lose additional weight
Inderal is frequently prescribed off-label to help manage the physical symptoms of performance anxiety, also known as stage fright
While it doesnt include injection reminders, notes can help track patterns
Insurance authorization for GLP-1 agonists typically requires meeting specific criteria for diabetes or obesity (BMI thresholds and comorbidities), not lymphedema diagnosis alone
